---
layout: page
title: Publications
description: Ryan Sun's publications
---


### <a name="articles"></a>Journal Articles

**Sun, R.**\*, Bouchard, M.B.\*, Hillman, E.M.C.
SPLASSH: open source software for camera-based high-speed, multispectral in-vivo optical image acquisition. 
*Biomedical Optics Express 2010*; 1(2): 375-397.

Wang, Z., Claus-Henn, B., Wang, C., Wei, Y., Su, L., **Sun, R.**, Chen, H., Wagner, P.J., Lu, Q., Lin, X., Wright, R., Bellinger, D., Kile, M., Mazumdar, M., Tellez-Rojo, M.M., Schaas, L., Christiani, D.C. 
Genome-wide gene by Pb exposure interaction analysis identifies UNC5D as a candidate gene for neurodevelopment.
*Environmental Health* 2-17; 16(1): 81.

**Sun, R.**, Carroll, R.J., Christiani, D.C., Lin, X. Testing for gene-environment interaction under exposure misspecification.
*Biometrics* 2018; 74(2): 653-662.

Orkaby, A., Rich, M.W., **Sun, R.**, Lux, E., Wei, L.J., Kim, D.H. Pravastin for primary prevention in older adults: restricted mean survival time analysis. 
*Journal of the American Geriatric Society* 2018; 66(10): 1987-1991.

**Sun, R.**, Wang, Z., Claus-Henn, B., Su, L., Lu, Q., Lin, X., Wright, R., Bellinger, D., Kile, M., Mazumdar, M., Tellez-Rojo, M.M., Schnaas, L., Christiani, D.C. 
Identification of novel loci associated with infant cognitive ability. 
*Molecular Psychiatry* Molecular Psychiatry 2018; 1-10.

**Sun, R.**, Hui, S., Bader, G., Lin, X., Kraft, P.
Powerful gene set analysis in GWAS with the Generalized Berk-Jones statistic.
*PLOS Genetics* 2019; 15(3): e1007530.

Gaynor, S.\*; **Sun, R.**\*, Lin, X., Quackenbush, J. Identification of differentially expressed gene sets using the Generalized Berk-Jones statistic.
*Bioinformatics* 2019; 35(22): 4568-4576.

**Sun, R.**, Lin, X. Set-based tests for genetic association using the Generalized Berk-Jones statistic.
*Journal of the American Statistical Association* 2020; 115(53): 1079-1091.

Park, H-R., Panganibana, R.A., **Sun, R.**, Shumyatcher, M., Himes, B.E., Christiani, D.C., Lu, Q. 
MicroRNA-124 protects neural cells against arsenic-induced endoplasmic reticulum stress and cytotoxicity in vitro and is associated with neurodevelopmental outcomes in children. *Scientific Reports* 2020; 10(1): 1-11.

Li, X., Li, Z., Zhou, H., Gaynor, S., Liu, Y., Chen, H., **Sun, R.**, ..., Lin, X.
Dynamic incorporation of multiple in-silico functional annotations empowers rare variant association analysis of large whole genome sequencing studies at scale. *Nature Genetics* 2020; 52(9): 969-983.

Colina, A., Hwang H., Wang, H., Katz, M., **Sun, R.**, Lee, J., Tzeng, C., Wolff, R., Raghav, K., Overman, M. 
Natural history and prognostic factors for localized small bowel adenocarcinoma. *ESMO Open* 2020; 5(6): e000960.

Deng, Q., Han, G., Puebla-Osorio, N., Ma, M.C.J., Strati, P., Chasen, B., Dai, E., Dang, M., Jain, N., Yang, H., Wang, Y., Zhang, S., Wang, R., Chen, R., Showell, H., Ghosh, S., Patchva, S., Zhang, Q., **Sun, R.**, ..., Green, M.R.
Characteristics of anti-CD19 CAR T-cell infusion products associated with efficacy and toxicity in patients with large B-cell lymphomas. *Nature Medicine* 2020; 26(12): 18878-1887

Zhu, L., Cai, D., Li, Y., Tong, X., **Sun, R.**, Srivastava, D., Hudson, M. 
Maximum likelihood estimation for the proportional odds model with mixed interval-censored failure time data. *Journal of Applied Statistics* 2021; 48(8):1496-1512.

**Sun, R.**, Xu, M., Li, X., Gaynor, S., Zhou, H., Bosse, Y., Lam, S., Tsao, M., Tardon, A., Chen, C., Doherty, J., Goodman, G., Egil Bojesen, S., Teresa, M.T., Johansson, M., Field, J.K., Bickeboller, H., Wichmann, H., Risch, A., Rennert, G., Arnold, S., Wu, X., Melander, O., Brunnstr Ìˆom, H., Marchand, L.L., Zong, X., Liu, G., Andrew, A., Duell, E., Kiemeney, L.A., Shen, H., Haugen, A., Johansson, M., Grankvist, K., Caporaso, N., Woll, P., Teare, M.D., Scelo, G., Hong, Y., Yuan, J., Lazarus, P., Schabath, M.B., Aldrich, M.C., Albanes, D., Brennan, P., Barbie, D., Mak, R., Hung, R.J., Amos, C.I., Christiani, D.C., Lin, X. 
Identification of inflammation and immune-related risk variants associated with squamous cell lung cancer. *Genetic Epidemiology* 2021; 45(1): 99-114.

Kim, D., Li, X., Bian, S., Wei, L.J., **Sun, R**. 
Effect of dementia drugs on nursing home placement: what is the meaningful metric? *JAMA Network Open* 2021; 4(1): e2034745.

Strati, S., Ahmed, S., Furqan, F., ..., **Sun, R.**, Claussen, C., Hawkins, M., Johnson, N., Singh, P., Mistry, H., Johncy, S., Adkins, S., Kebriaei, P., Shpall, E., Green, M., Flowers, C., Westin, J., Neelapu, S. 
Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor t-cell therapy in large b-cell lymphoma. *Blood* 2021; 137(23): 3272-3276.

Alhalabi, O., Soomro, Z., **Sun, R.**, Hasanov, E., Albittar, A., Tripathy, D., Valero, V., Ibrahim, N. 
Outcomes of changing systemic therapy in patients with relapsed breast cancer and 1 to 3 brain metastases. *NPJ Breast Cancer* 2021; 7(1): 1-5.

Yam, C., Rauch, G., Rahman, T., Karuturi, M., Ravenberg, E., White, J., Clayborn, A., McCarthy, P., Abouharb, S., Lim, B., Litton, J., Ramirez, D., Saleem, S., Stec, J., Symmans, W., Huo, L., Damodaran, S., **Sun, R.**, Moulder, S. 
A phase II study of mirvetuximab soravtansine in triple- negative breast cancer. *Investigational New Drugs* 2021; 39(2): 509-515.

Han, G., Yang, G., Hao, D., Lu, Y., Thein, K., Chen, J., **Sun, R.**, ..., Wang, L. 
9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. *Nature Communications* 2021; 12(1): 1-19.

Xu, M., Tapia, C., Hajjar, J., ..., **Sun, R.**, Karp, D., Koay, E., Yang, Y., Wistuba, I., Hwu, P., Meric-Bernstam, F., Naing, A. 
Implementation of a novel web-based lesion selection tool to improve acquisition of biopsies. *Journal of Immunotherapy and Precision Oncology* 2021: 4(2): 45-52.

Yam, Y., Yen, E., Chang, T., ..., **Sun, R.**, Moulder, S., Mittendorf E. 
Immune phenotype and response to neoadjuvant therapy in triple-negative breast cancer. *Clinical Cancer Research* 2021; 27(19): 5356-5375.

**Sun, R.**\*, McCaw, Z.\*, Tian, L., Uno, H., Hong, F., Kim, D., Wei, L.J. 
Moving beyond conventional stratified analysis to assess the treatment effect in a comparative oncology study. *Journal for Immunotherapy of Cancer* 2021; 9(11): e003323.

Kaseb, A., Hasanov, E., Cao, H., ..., **Sun, R.**, Vittorio, C., Beretta, L., Yao, J., Wolff, R., Allison, J., Sharma, P. 
Perioperative nivolumab monotherapy plus ipilimumab in resectable hepatocellular carcinoma. *The Lancet Gastroenterology & Hepatology* 2022; 7(3):208-218.

Li, Y., Xiao, X., Li, J., ..., **Sun, R.**, ..., Willey, J., Gaba, C., Amos, C. 
Genome-wide interaction analysis identified low-frequency variants with sex disparity in lung cancer risk. *Human Molecular Genetics* 2022; 31(16):2831-2843.

Grover, P., Veilleux O., Tian, L., **Sun, R.**, Previtera, M., Curran, E., Muffly, L. 
Chimeric antigen receptor-T cell therapy in adults with B-cell acute lymphoblastic leukemia: a systematic review. *Blood Advances* 2022 6(5):1608-1618.

McCaw, Z., Gaynor, S., **Sun, R.**, Lin X. 
Cross-tissue eQTL mapping in the presence of missing data via surrogate outcome analysis. *Biometrics* 2022+ (in press).

Li, X., Yung G., Zhou H., **Sun, R.**, Li, Z., Liu X., Ionita-Laza, I., Lin X. 
A multi-dimensional integrative scoring framework for predicting functional variants in the human genome. *American Journal of Human Genetics* 2022; 109(3):446-456.

**Sun, R.**, Liang, Z., Li, Y., Yutaka, Y., Robison, L. Inference for set-based effects in genetic association studies with interval-censored outcomes. *Biometrics* 2022+ (in press).

Yam, C.,\* Abuhadra, N.,\* **Sun, R.,*** Ding, Q., ..., Huo, L., Moulder, S., Chang, J. Molecular characterization and prospective evaluation of pathological response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer. *Clinical Cancer Research* 2022; 28(13):2878-2889.

Huang, B.,\* **Sun, R.,**\* Claggett, B., Tian, L., Ludmir, E.B., Wei, L.J. Handling informative premature treatment or study discontinuation for assessing between-group differences in a comparative oncology trial. *JAMA Oncology* 2022; 8(10):1502-1503.

**Sun, R.**, Shi, A.,Lin, X. Differences in genetic set-based inference for sparse signals when testing sets of outcomes compared to sets of explanatory factors. *Biostatistics* 2022; kxac036.

Li, Z., Li, X., Zhou, H., Gaynor, S.M., Selvaraj, M.S., Arapoglou, T., Quick, C., Liu, Y., Chen, H., **Sun, R.**, ..., Lin, X. A framework for detecting noncoding rare variant associations of large-scale whole-genome sequencing studies. *Nature Genetics* 2022; 19(12):1599-1611.

Cherng, H.J., **Sun, R.**, Sugg, B., Yang, H., Irwin, R., Deng, Q., Fayad, L., Fowler, N., Par- mar, S., Steiner, R., Hagemeister, F., Nair, R., Lee, H.J., Rodriguez, M., Samaniego, F., Iyer, S., Flowers, C., Wang, L., Nasoupil, L.J., Neelapu, S.S., Ahmed, S., Strati, P., Green, M.R., Westin, J. Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma. *Blood* 2022; 140(5):504-515.

Byun, J., Han, Y., Li, Y., Xia, J., Xiao, X., **Sun, R.**, ..., Amos, C. Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer. *Nature Genetics* 2022; 54(8):1167-1177.

Westin, J., Davis, R., Feng, L., ..., **Sun, R.**, Scott, D., Flowers, C., Neelapu, S., Green, M.R. SmartStart: rituximab, lenalidomide, and ibrutinib in large B-cell lymphoma. *Journal of Clinical Oncology* 2023; 41(4):745-755.

Sohn, A.J., Taherian, M., Katz, M.H.G, ..., **Sun, R.**, Maitra, A., Wang, H. Integrated pathologic score effectively stratifies patients with pancreatic ductal adenocarcinoma who received neoadjuant therapy and pancreaticoduodenectomy. *American Journal of Surgical Pathology* 2023; 47(4):421- 430.

Raghav, K., Ou, F., Venook, A.P., Innocenti, F., **Sun, R.**, Lenz, H., Kopetz, S. Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance). *Journal of Clinical Oncology* 2023; 41(3):472-478.

Li, X., Quick C., Zhou, H., Gaynor, S.M., Lu, Y., Chen, H., **Sun, R.**, ..., Lin, X. Powerful, scalable and resource-efficient meta-analysis of rare variant associations in large whole-genome sequencing studies. *Nature Genetics* 2023; 55(1):154-164.

Parseghian, C.,\* **Sun, R.**,\*, Woods, M.,\* Napolitano, S.,\* Nunez, S., Sorokin, A., Kanikarla, P., Eluri, M., Morris, V.K., Willis, J., Evilar, E., Rehn, M., Ang, A., Troiani, T., Kopetz, S. Resistance mechanisms to antiâ€“epidermal growth factor receptor therapy in RAS/RAF wild-type colorectal cancer vary by regimen and line of therapy. *Journal of Clinical Oncology* 2023; 41(3):460-471.

Yam, C., Mittendorf, E.A., Garber, H.R., **Sun, R.**, Damodaran, S., Murthy, R.K., Ramirez, D., Karuturi, M., Layman, R.M., Ibrahim, N., Rauch, G.M. A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. *Breast Cancer Research and Treatment* 2023; 1-13.

Han, Y., Byun, J., Zhu, C., **Sun, R.**, Roh, J.Y., Cordell, H.J., Lee, H.S., Shaw, V.R., Kang, S.W., Razjouyan, J., ..., Amos, C.I. Multitrait genome-wide analyses identify new susceptibility loci and candidate drugs to primary sclerosing cholangitis. *Nature Communications* 2023; 14(1):1069.

Patni, T., Lee, C.T., Li, Y., Kaste, S., Zhu, L., **Sun, R.**, Hudson, M.M., Ness, K.K., Neumann, A., Robison, L.L. Factors for poor oral health in long-term childhood cancer survivors. *BMC Oral Health* 2023; 23(1):1-11.

Zeineddine, F.A., Zeineddine, M.A., Yousef, A., Gu, Y., Chowdhury, S., Dasari, A., Huey, R.W., Johnson, B., Kee, B., Lee, M.S., ..., **Sun, R.**, Kopetz, S., Shen, J.P. Survival improvement for patients with metastatic colorectal cancer over twenty years. *NPJ Precision Oncology* 2023; 7(1):16.

**Sun, R.**, Sun, D., Liang, Z., Sun, J. Regression analysis of general mixed recurrent event data. *Lifetime Data Analysis* 2023+ (in press)

Napolitano, S., Parikh, A.R., Henry, J., Parseghian, C.M., Willis, J., Raghav, K.P., Morris, V.K., Johnson, B., Kee, B.K., Dasari, A.N., Overman, M.J., Luthra, R., Drusbosky, L.M., Corcoran, R.B., Kopetz, S., **Sun, R.** A novel clinical tool to estimate risk of false negative KRAS mutations in circulating tumor DNA testing. *JCO Precision Oncology* 2023+ (in press)

Chamseddine, S., Mohamed, Y.I., Lee, S.S., Yao, J.C., Hu, Z.I., Cao, H.S.T., Xiao, L., **Sun, R.**, Morris, J.S., Hatia, R.I., ..., Kaseb, A.O. Clinical and Prognostic Biomarker Value of Blood Circulating Inflammatory Cytokines in Hepatocellular Carcinoma. *Oncology* 2023+ (in press)

Wang, H., Moniruzzaman, R., Li, L., Ji, B., Liu, Y., Zuo, X., Abbasgholizadeh, R., Zhao, J., Liu, G., Wang, R., Tang, H., **Sun, R.**, ..., Wang, H.Hematopoietic progenitor kinase 1 inhibits the development and progression of pancreatic intraepithelial neoplasia. *The Journal of Clinical Investigation* 2023+ (in press)

Strati, P., Jallouk, A., Deng, Q., Li, X., Feng, L., **Sun, R.**, Adkins, S., Johncy, S., Cain, T., Steiner, R.E., Ahmed, S. A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large b-cell lymphoma. *Blood Advances* 2023+ (in press)

#### Papers Receiving Peer Review

*Sun, R.*, McCaw, Z., Lin, X. Large-scale testing of composite null hypothesis in genetic asso- ciation studies. In revision for Journal of the American Statistical Association.

Choi, J., Xu, Z., *Sun, R.* Set-based inference for multiple interval-censored outcomes in genetic association studies. In revision for Statistics in Medicine.

#### Published Correspondence

**Sun, R.**, Horiguchi, M., Wei, L.J.
Interpreting the benefit of frifluirdine/tipiracil in metastatic colorectal cancer with respect to progression-free survival and overall survival.
*Journal of Clinical Oncology* 2018; 36(13): 1378.

**Sun, R.**, Rich, M.W., Wei, L.J.  Pembrolizumab plus chemotherapy in lung cancer.
*New England Journal of Medicine* 2018; 379(11): e18.

**Sun, R.**, Nie, L., Huang, B., Kim, D.H., Wei, L.J. Quantifying immunoscore performance.
*The Lancet* 2018; 392(10158): 1624.

**Sun, R.**, Wei, L.J. Regional Hyperthermia With Neoadjuvant Chemotherapy for Treatment of Soft Tissue Sarcoma.
*JAMA Oncology* 2019; 5(1): 112-113.

**Sun, R.**, Zhu, H., Wei, L.J. Assessing the prognostic value of automated bone scan index in prostate cancer.
*JAMA Oncology* 2019; 5(2): 270.

**Sun, R.**, Orkaby, A.O., Kim, D.H., Zhu, H., Wei, L.J. Interpreting non-inferiority of biodegradable- polymer stents to durable-polymer stents.
*The Lancet* 2019; 393(10184): 1932-1933.

**Sun, R.**, Lee, H., Wei, L.J. Interpreting the long-term prognostic value of total mesorectal excision plane quality in rectal adenocarcinoma.
*JAMA Surgery* 2019; 154(1): 96.

**Sun, R.**, Kim, D.H., and Wei, L.J. Analysis of overall survival benefit of abemaciclib plus fulvestrant in hormone receptor-positive, ERBB-2 negative breast cancer. 
*JAMA Oncology* 2020; 6(7): 1121-1122.

**Sun, R.**, Messick, C., and Wei, L.J. Quantifying benefit from two-stage turnbull-cutait pull-through coloanal anastomosis for low rectal cancer. 
*JAMA Surgery* 2021; 156(2): 202-203.

**Sun, R.**, Tian, L., and Wei, L.J. Evaluating long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma. *JAMA Surgery* 2022; 157(5):458-459.

**Sun, R.** and Wei, L.J. Quantifying clinical utility of enzalutamide for overall survival in metastatic hormone-sensitive prostate cancer. *Journal of Clinical Oncology* 2022; 40(36):4278-4279.

**Sun, R.** and Wei, L.J. Quantifying clinical utility of adjuvant abemaciclib in patients with high-risk early breast cancer who received neoadjuvant chemotherapy. *JAMA Oncology* 2022; 8(11):1701.

**Sun, R.** and Wei, L.J. Pembrolizumab in triple-negative breast cancer. *New England Journal of Medicine* 2023; 387(15):1435.

**Sun, R.**, Huang, B., Wei, L.J. Comparing short- and long-term treatment duration of bevacizumab for advanced ovarian cancer. *Journal of Clinical Oncology* 2023; 41(10):1952-1953.

**Sun, R.** and Wei, L.J. Efficacy, safety, and analysis issues in a study of intraoperative hyperthermic intraperitoneal chemotherapy for locally advanced colon cancer. *JAMA Surgery* 2023+






\*Indicates equal contribution as first authors.
